WO2018124142A1 - 高レバウジオシドc含有ステビア植物 - Google Patents
高レバウジオシドc含有ステビア植物 Download PDFInfo
- Publication number
- WO2018124142A1 WO2018124142A1 PCT/JP2017/046805 JP2017046805W WO2018124142A1 WO 2018124142 A1 WO2018124142 A1 WO 2018124142A1 JP 2017046805 W JP2017046805 W JP 2017046805W WO 2018124142 A1 WO2018124142 A1 WO 2018124142A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- rebaudioside
- plant
- stevia
- present
- extract
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01H—NEW PLANTS OR NON-TRANSGENIC PROCESSES FOR OBTAINING THEM; PLANT REPRODUCTION BY TISSUE CULTURE TECHNIQUES
- A01H5/00—Angiosperms, i.e. flowering plants, characterised by their plant parts; Angiosperms characterised otherwise than by their botanic taxonomy
- A01H5/10—Seeds
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01H—NEW PLANTS OR NON-TRANSGENIC PROCESSES FOR OBTAINING THEM; PLANT REPRODUCTION BY TISSUE CULTURE TECHNIQUES
- A01H5/00—Angiosperms, i.e. flowering plants, characterised by their plant parts; Angiosperms characterised otherwise than by their botanic taxonomy
- A01H5/12—Leaves
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01H—NEW PLANTS OR NON-TRANSGENIC PROCESSES FOR OBTAINING THEM; PLANT REPRODUCTION BY TISSUE CULTURE TECHNIQUES
- A01H6/00—Angiosperms, i.e. flowering plants, characterised by their botanic taxonomy
- A01H6/14—Asteraceae or Compositae, e.g. safflower, sunflower, artichoke or lettuce
- A01H6/1488—Stevia
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L27/00—Spices; Flavouring agents or condiments; Artificial sweetening agents; Table salts; Dietetic salt substitutes; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q13/00—Formulations or additives for perfume preparations
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/04—Plant cells or tissues
Definitions
- the present invention relates to a stevia plant having a high rebaudioside C content.
- Patent Document 1 discloses a functional sweetener composition containing a vitamin, a high-intensity sweetener, and a sweet taste improving composition.
- Rebaudioside (Rebaudioside, hereinafter also referred to as “Reb”) is known as a sweet component contained in stevia extract.
- Stevia extract is extracted and purified from dried Stevia leaves.
- Stevia is a perennial plant of Chrysanthemum that originated in Paraguay, South America, and its scientific name is Stevia Rebaudiana Bertoni.
- Stevia contains ingredients that are about 300 times more sweet than sugar and is cultivated to extract these sweet ingredients and use them as natural sweeteners.
- As Reb the presence of various glycosides such as RebA, RebB, RebC, RebD, RebE, and RebM has been reported (Special Tables 2012-504552).
- RebA has been evaluated as a sweetener having high sweetness and good quality sweetness, and is widely used.
- Other Rebs are also becoming known to have their own sweetness and associated taste.
- Patent Document 3 stevia plants containing 3 to 8% by weight of rebaudioside C per dry leaf are known.
- rebaudioside C (hereinafter sometimes referred to as “RebC”) contained in stevia extract is sweet. Found to improve the pull-up. Therefore, acquisition of a stevia plant containing even more rebaudioside C, means for producing such a plant, dry leaves obtained from such plants, food containing rebaudioside C obtained from these dry leaves It is desirable to provide food and beverages.
- the present application provides a high rebaudioside C-containing non-genetically modified stevia plant containing rebaudioside C at a higher content than wild type stevia species, and a method for producing and screening the plant.
- acquisition of a stevia plant containing more rebaudioside C, means for producing such a plant, dried leaves obtained from such a plant, rebaudioside C obtained from the dried leaves are included Food and beverages can be provided.
- High rebaudioside C-containing non-genetically modified stevia plant of the present invention is a high rebaudioside C-containing non-genetically modified stevia plant containing 20% or more of rebaudioside C compared to wild-type stevia species, and
- the plant body (hereinafter referred to as “plant body of the present invention”) in which the ratio of rebaudioside C in the total steviol glycoside is 40% or more is provided.
- the stevia plant of the present invention is a species derived from a wild-type stevia plant, but the gene is mutated so that rebaudioside C is high. And the variation
- Contains 20% or more of rebaudioside C compared to wild-type stevia species means that it is contained per unit amount (for example, 10 ml) of the extract obtained from fresh leaves (non-dried leaves) of wild-type stevia plants.
- the amount of rebaudioside C to be used is a standard (concentration)
- the same unit amount of the extract obtained from the fresh leaves (non-dried leaves) of the stevia plant of the present invention obtained from the leaves of the wild-type stevia plant
- the amount (concentration) of rebaudioside C contained in the same amount as the extracted liquid is higher by 20% or more.
- the stevia plant of the present invention has rebaudioside C of 20% or more, 22% or more, 24% or more, 26% or more, 28% or more, 30% or more, 32% or more, 34% compared to wild type stevia species. 36% or more, 38% or more, 40% or more, 42% or more, 44% or more, 46% or more, 48% or more, 50% or more, 52% or more, 54% or more, 56% or more, 58% or more,
- the content may be 60% or more, 62% or more, 64% or more, 66% or more, 68% or more, 70% or more.
- the ratio of rebaudioside C in the total steviol glycoside is 40% or more
- the total steviol glycoside present in the extract obtained from the fresh leaves (non-dried leaves) of the stevia plant of the present invention means that rebaudioside C is present at a ratio of 40% or more with respect to body weight.
- the total steviol glycoside does not include unknown steviol glycosides, nor does it include steviol glycosides that are present below the detection limit.
- the total steviol glycoside includes rebaudioside A, rebaudioside B, rebaudioside C, rebaudioside D, rebaudioside E, rebaudioside F, rebaudioside I, rebaudioside J, rebaudioside K, rebaudioside N, rebaudioside M, rebaudioside O, rebaudioside O, It is any combination of two or more selected from the group consisting of rebaudioside R, dulcoside A, rubusoside, steviol, steviolmonoside, steviolbioside and stevioside.
- the total steviol glycoside consists of rebaudioside A, rebaudioside B, rebaudioside C, rebaudioside D, rebaudioside F, rebaudioside M and steviol
- the total steviol glycoside is rebaudioside A.
- Rebaudioside B, rebaudioside C, rebaudioside D, rebaudioside F, rebaudioside M, rebaudioside N, rebaudioside O and steviol is rebaudioside A.
- rebaudioside C in the plant of the present invention is as described above.
- rebaudioside C is 7% by weight or more and 8% by weight with respect to the weight of the dry leaves. %, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18% %, 19% by weight, or 20% by weight or more.
- the dry leaves of the plant body of the present invention is a moisture content of 10% by weight or less, 7% by weight or less, 5% by weight or less, 4% by weight or less by drying the fresh leaves of the Stevia plant of the present invention, 3% by weight or less, 2% by weight or less, 1% by weight or less.
- the moisture content of the dried leaves of the plant of the present invention is 3 to 4% by weight.
- the plant body of the present invention may have at least one of the following characteristics in addition to the above characteristics related to rebaudioside C.
- the content (production amount) of rebaudioside A is lower than that of wild-type stevia species. More specifically, the rebaudioside A content (for example, weight concentration in dry leaves) is about 40% or more, about 50% or more, about 60% or more, about 70% or more, or about More than 80% lower.
- the content (production amount) of stevioside is lower than that of wild type stevia species. More specifically, the content of stevioside (for example, the weight concentration in dried leaves) is lower by about 50% or more, about 60% or more, about 70% or more, or about 80% or more compared to wild type stevia species.
- the content (production amount) of rebaudioside F is higher than that of wild-type stevia species. More specifically, the rebaudioside F content (for example, the weight concentration in dry leaves) is about 2 times or more, about 3 times or more, about 4 times or more, about 5 times or more, or about More than 6 times higher.
- the ratio of rebaudioside A in the total steviol glycoside is lower than that of wild type stevia species. More specifically, the proportion of rebaudioside A in the total steviol glycosides (for example, in dry leaves) is about 8% or more, about 20% or more, about 30% or more, about 40% or more compared to wild type stevia species. About 50% or more, about 60% or more, or about 70% or more. (5) The ratio of stevioside in the total steviol glycoside is lower than that of wild type stevia species.
- the proportion of stevioside in the total steviol glycoside (for example, in dry leaves) compared to wild type stevia species is about 30% or more, about 40% or more, about 50% or more, about 60% or more, Or about 70% or more lower.
- the ratio of rebaudioside F in the total steviol glycoside is higher than that of wild-type stevia. More specifically, the proportion of rebaudioside F in the total steviol glycoside (eg, in dry leaves, etc.) is about 3 times or more, about 4 times or more, about 5 times or more, or about 6 compared to wild type stevia species. More than twice as low.
- the above characteristics (1) to (6) indicate that the plurality of individuals of the plant of the present invention can be obtained by comparing the specific plant of the present invention with a specific individual of the wild type Stevia species. It may be based on a comparison between an arithmetic average value in a group consisting of and an arithmetic average value in a group consisting of a plurality of individuals of the wild type Stevia species.
- the plant of the present invention has a low rebaudioside A and stevioside content (production amount) and a rebaudioside F content (production amount) in addition to the above-described characteristics relating to rebaudioside C. ) And / or the ratio of rebaudioside A and stevioside in the total steviol glycosides is low and the ratio of rebaudioside F in the total steviol glycosides is high compared to wild type stevia species.
- the stevia plant of the present invention is a species derived from a wild-type stevia plant, and a gene is mutated so that rebaudioside C is high.
- the gene mutation occurs under natural conditions or by non-genetic recombination techniques.
- the gene mutation is as shown in SEQ ID NO: 1 (hereinafter referred to as “gene polymorphism of the present invention”).
- the nucleotide sequence of SEQ ID NO: 1 is a single nucleotide polymorphism (SNP: hereinafter referred to as “the present invention”) in which the 60th nucleotide sequence of the corresponding nucleotide sequence of the wild type allele (SEQ ID NO: 2) is mutated from wild type A to T. SNP "). Therefore, the stevia plant of the present invention has the polymorphism shown in SEQ ID NO: 1 in the genome. These polymorphisms have been confirmed in the Examples to have a statistical correlation with the phenotype of high rebaudioside C content.
- the stevia plant of the present invention may have the gene polymorphism in a heterozygous form or a homozygous form.
- a plant having the gene polymorphism in a homozygous form tends to have a higher rebaudioside C content than a heterozygous form.
- These gene polymorphisms can be detected by the PCR method, TaqMan PCR method, sequencing method, microarray method, invader method, TILLING method, etc., but the detection method is not limited thereto. Details of the gene polymorphism detection method will be described later.
- examples of the “non-genetic recombination technique” include a method of inducing a mutation in a gene of a host cell (or host plant) without introducing a foreign gene.
- examples of such a method include a method of causing a plant cell mutagen to act.
- mutagens include ethylene methanesulfonic acid (EMS) and sodium azide.
- EMS ethylene methane sulfonate
- the treatment time is 1 to 48 hours, 2 to 36 hours, 3 to 30 hours, 4 to 28 hours, 5 to 26 hours, and 6 to 24 hours.
- the treatment procedure itself is known, but can be carried out by immersing the water-seeded seed that has undergone the water absorption process in a treatment solution containing a mutagen at the above concentration for the treatment time.
- a non-genetic recombination technique a method of irradiating a plant cell with radiation or light such as X-rays, ⁇ -rays, and ultraviolet rays can be used.
- the irradiation intensity is 0.01 ⁇ 100Gr, 0.03 ⁇ 75Gr, 0.05 ⁇ 50Gr, 0.07 ⁇ 25Gr, 0.09 ⁇ 20Gr, 0.1 ⁇ 15Gr, 0.1 ⁇ 10Gr, 0.5 ⁇ 10Gr, 1 ⁇ 10Gr, and the irradiation distance is 1cm ⁇ 200m , 5cm ⁇ 100m ⁇ 7cm ⁇ 75m ⁇ 9cm ⁇ 50m ⁇ 10cm ⁇ 30m ⁇ 10cm ⁇ 20m ⁇ 10cm ⁇ 10m ⁇ Irradiation time is 1 minute ⁇ 2 years ⁇ 2 minutes ⁇ 1 year ⁇ 3 minutes ⁇ 0.5 years ⁇ 4 minutes ⁇ 1 month, 5 minutes to 2 weeks, 10 minutes to 1 week.
- the intensity, distance, and time of irradiation vary depending on the radiation line type and the state to be irradiated (cells, callus, plant body), but can be appropriately adjusted by those skilled in the art.
- techniques such as cell fusion, sputum culture (haploid growth), and far-cross hybridization (haploid growth) are also known.
- plant cells may be mutated during culture, it is preferable to return the plant cells to plant individuals for more stable trait maintenance.
- the plant body of the present invention is a non-genetically modified Stevia plant body.
- a plant body obtained by performing genetic recombination afterwards using the plant body of the present invention as a host for example, the plant body of the present invention as a host). Plants that have been genetically modified and further added with other traits) are not excluded from the scope of the present invention.
- Rebaudioside C can be extracted in the form of an extract by reacting the fresh or dried leaves of the plant of the present invention with an appropriate solvent (an aqueous solvent such as water or an organic solvent such as alcohol, ether and acetone). It can.
- an aqueous solvent such as water or an organic solvent such as alcohol, ether and acetone
- ethyl acetate and other organic solvents water gradient, high performance liquid chromatography (HPLC), gas chromatography, time-of-flight mass spectrometry (Time- Rebaudioside C can be purified by using a known method such as of-flight mass spectrometry (TOF-MS) or ultra (high) performance liquid chromatography (UPLC).
- the rebaudioside C content according to the present invention can be measured by the method described in WO2016 / 090460 or the method described in Examples described later. Specifically, it can be measured by sampling fresh leaves from the stevia plant of the present invention and performing LC / MS-MS.
- the plant body of the present invention includes not only the whole plant body but also a plant organ (eg, leaf, petal, stem, root, seed, etc.), plant tissue (eg, epidermis, phloem, soft tissue, xylem, vascular bundle, fence-like shape) Tissue, spongy tissue, etc.) or various forms of plant cells (eg, suspension culture cells), protoplasts, leaf sections, callus, and the like.
- a plant organ eg, leaf, petal, stem, root, seed, etc.
- plant tissue eg, epidermis, phloem, soft tissue, xylem, vascular bundle, fence-like shape
- Tissue eg, spongy tissue, etc.
- various forms of plant cells eg, suspension culture cells
- protoplasts eg, leaf sections, callus, and the like.
- the plant body of the present invention may include a tissue culture or a plant culture cell. It is because a plant body can be regenerated by culturing such tissue culture or plant culture cells.
- tissue culture or plant culture cells of the plant of the present invention include embryos, meristem cells, pollen, leaves, roots, root tips, petals, protoplasts, leaf sections, and callus. It is not limited.
- the present invention includes a step of crossing a stevia plant body of the present invention with a second stevia plant body, wherein 20% of rebaudioside C is compared with a wild type stevia species.
- a method for producing a high rebaudioside C-containing stevia plant containing a high content as described above (hereinafter referred to as “production method of the present invention”) is provided.
- production method of the present invention A “high rebaudioside C-containing stevia plant containing 20% or more of rebaudioside C compared to the wild-type stevia species” produced by this method has the same phenotype and genetic properties as the plant of the present invention.
- the phenotype of the plant produced by the production method of the present invention contains rebaudioside C at a content 20% or more higher than that of wild-type stevia species, and the ratio of rebaudioside C in the total steviol glycosides. Is 40% or more.
- containing rebaudioside C at a content 20% or more higher than that of wild-type stevia is as described above.
- the ratio of rebaudioside C in the total steviol glycoside is 40% or more” is as described above.
- the rebaudioside C is 7% by weight or more, 8% by weight or more, 9% by weight or more, 10% by weight or more, based on the weight of the dried leaves. 11% or more, 12% or more, 13% or more, 14% or more, 15% or more, 16% or more, 17% or more, 18% or more, 19% or more, 20% or more May be present in an amount.
- the definition of dry leaves is as described above.
- the genetic property of the plant produced by the production method of the present invention is that it has the gene polymorphism shown in SEQ ID NO: 1.
- the plant produced by the production method of the present invention may have the gene polymorphism in a heterozygous form or a homozygous form.
- crossing means that a plant body of the present invention and a second plant body are crossed to produce a child plant body (plant body produced by the production method of the present invention). It means getting.
- backcrossing is preferable.
- Backcross means that a child plant born between the plant of the present invention and the second plant is further converted into a plant of the present invention (that is, a plant having the gene polymorphism of the present invention). This is a technique for producing a homozygous plant of the gene polymorphism of the present invention by crossing.
- the second plant used in the production method of the present invention has the same phenotype and genetic properties as the plant of the present invention, it is substantially backcrossed.
- the gene polymorphism of the present invention is inherited according to Mendel's law, and a phenotype correlated with the gene polymorphism, that is, a phenotype containing high rebaudioside C is also inherited according to Mendel's law.
- the plant of the present invention can be produced by self-propagation.
- Self-propagation can be performed by causing the stamen pollen of the plant of the present invention to self-pollinate the pistil of the plant of the present invention.
- the plant produced by the production method of the present invention has the same phenotype and genetic properties as the plant of the present invention, the plant produced by the production method of the present invention is further replaced with a third stevia plant. It is also possible to produce a high rebaudioside C-containing stevia plant containing 20% or more of rebaudioside C in comparison with the wild-type stevia species.
- the plant body of the present invention can also be produced by regenerating the plant body by culturing the tissue culture or plant culture cell described above.
- the culture conditions are the same as the conditions for culturing wild-type stevia plant tissue culture or plant culture cells (Protocols for In Vitro cultures and secondary metabolite analysis of aromatic and medicinal plants, Method in molecular biology, vo. 1391, pp113-123.).
- Screening method of plant of the present invention The plant of the present invention and the plant having the same phenotype and genetic properties as the plant of the present invention are detected by detecting the gene polymorphism of the present invention from the tissue of the plant. Can be screened.
- “screening” means identifying the plant body of the present invention from other plant bodies and selecting the plant body of the present invention. Therefore, as another embodiment, the present invention provides a method for screening a high rebaudioside C-containing stevia plant comprising the step of identifying the polymorphism shown in SEQ ID NO: 1 in the genome of a test plant (hereinafter referred to as “the present invention”). Screening method) ”.
- the mutation site is included in an amplified probe obtained by amplifying at least one of the base sequence of the gene polymorphism of the present invention and / or the base sequence of the gene and its complementary sequence; A step of performing an amplification treatment and / or a hybridization treatment on the genome or cDNA library of the test Stevia plant using the prepared oligonucleotide primer; and (b) A method including a step of detecting a mutation site by analyzing the treated product.
- telomere extension reaction does not occur because the nucleotide at the 3 'end of the primer mismatches with the template.
- the sample template has a mutation. If no amplification product is present, it can be determined that the template has no mutation.
- the primer sequence is designed so that the SNP of the present invention does not overlap with the primer sequence and the gene polymorphism of the present invention can be PCR amplified, and the nucleotide sequence of the amplified nucleotide fragment is sequenced. Thus, the gene polymorphism of the present invention can be detected.
- PCR and agarose gel electrophoresis see: Sambrook, Fritsch and Maniatis, “Molecular Cloning: A Laboratory Manual” 2nd Edition (1989), Cold Spring Harbor Laboratory Press.
- TaqMan PCR is a method using a PCR reaction with fluorescently labeled allele-specific oligos and Taq DNA polymerase (Livak, KJ Genet. Anal. 14, 143 (1999); Morris T. et al., J Clin. Microbiol. 34, 2933 (1996)).
- the sequencing method is a method of analyzing the presence or absence of mutation by amplifying a region containing mutation by PCR and sequencing the DNA sequence using a dye terminator or the like (Sambrook, Fritsch and Maniatis, “Molecular Cloning: A Laboratory Manual ”2nd Edition (1989), Cold Spring Harbor Laboratory Press).
- a DNA microarray is one in which one end of a nucleotide probe is fixed in an array on a support, and includes a DNA chip, a Gene chip, a microchip, a bead array, and the like. By using a probe containing a sequence complementary to the gene polymorphism of the present invention, the presence or absence of the gene polymorphism of the present invention can be comprehensively detected.
- DNA microarray assays such as DNA chips include GeneChip assay (see Affymetrix; US Pat. Nos. 6,045,996, 5,925,525, and 5,858,659). GeneChip technology uses a miniaturized high-density microarray of oligonucleotide probes attached to a chip.
- the invader method is a special case in which two reporter probes specific to each allele of a gene polymorphism such as SNP and one invader probe are hybridized to the template DNA, and the DNA structure is recognized and cleaved.
- This method combines DNA cleavage with a Cleavase enzyme having a unique endonuclease activity (Livak, KJ Biomol. Eng. 14, 143-149 (1999); Morris T. et al., J. Clin. Microbiol. 34, 2933 (1996); Lyamichev, V. et al., Science, 260, 778-783 (1993), etc.).
- the TILLING (Targeting Induced Local Lesions IN Genomes) method is a method of screening mutation mismatches in the genome of a mutant group into which mutations have been introduced by PCR amplification and CEL I nuclease treatment.
- the extract containing rebaudioside C comprising the step of obtaining an extract from the plant of the present invention, or the seed or dried leaf of the plant.
- the method for producing the extract of the present invention comprising the step of purifying rebaudioside C from the extract obtained by the method of producing an extract of the present invention.
- the rebaudioside C-containing extract can be obtained by reacting an appropriate solvent (an aqueous solvent such as water or an organic solvent such as alcohol, ether and acetone) with the fresh or dried leaves of the plant body of the present invention.
- an appropriate solvent an aqueous solvent such as water or an organic solvent such as alcohol, ether and acetone
- the method described in WO2016 / 090460 or the method described in the examples described later can be referred to.
- rebaudioside C-containing extracts are extracted from ethyl acetate and other organic solvents: water gradient, high performance liquid chromatography (HPLC), gas chromatography, time-of-flight mass spectrometry (Time-of-Flight mass spectrometry)
- HPLC high performance liquid chromatography
- gas chromatography time-of-flight mass spectrometry
- time-of-Flight mass spectrometry time-of-Flight mass spectrometry
- the rebaudioside C can be purified by using a known method such as TOF-MS) or ultra high performance liquid chromatography (UPLC).
- the extract obtained by the method for producing an extract of the present invention contains rebaudioside C at a content 20% or more higher than that of the wild-type stevia species, and total steviol glycoside
- the ratio of rebaudioside C in the body is 40% or more.
- “containing rebaudioside C at a content 20% or more higher than that of wild-type stevia” is as described above.
- “the ratio of rebaudioside C in the total steviol glycoside is 40% or more” is as described above.
- the extract of the present invention is different in at least the ratio of rebaudioside C in the total steviol glycoside compared to the extract similarly extracted from the wild type stevia species, the extract similarly extracted from the wild type stevia species It is thought that characteristics such as taste characteristics are different.
- the present invention includes a step of mixing the extract of the present invention and / or rebaudioside C obtained by the method for producing rebaudioside C of the present invention and other components, a pharmaceutical, a fragrance, or a food or drink A method for manufacturing a product is provided. Furthermore, this invention provides the novel pharmaceutical, the fragrance
- the food and drink means beverages and foods. Therefore, in one embodiment, the present invention provides a novel pharmaceutical product, fragrance, beverage or food, and provides a method for producing the pharmaceutical product, fragrance, beverage or food.
- Non-natural ingredients include non-naturally occurring compounds such as synthetic additives such as synthetic flavors and synthetic preservatives, fermentation products and the like.
- the dosage form of a pharmaceutical product is not particularly limited, and can be any dosage form such as a solution, paste, gel, solid, and powder.
- the pharmaceutical product (pharmaceutical composition) of the present invention includes oil, lotion, cream, emulsion, gel, shampoo, hair rinse, hair conditioner, enamel, foundation, lipstick, funny, pack, ointment, powder, toothpaste, aerosol, cleansing In addition to skin external preparations such as foam, it can be used for bath preparations, hair nourishing agents, skin cosmetics, sunscreen agents, and the like.
- the pharmaceutical product (pharmaceutical composition) of the present invention may further contain other pharmaceutically active components (for example, anti-inflammatory components) or auxiliary components (for example, lubricating components and carrier components) as necessary.
- the pharmaceutically active ingredient or auxiliary ingredient may be a natural ingredient or a non-natural ingredient.
- beverages include, but are not limited to, fruit juice beverages, soft drinks, sports beverages, tea beverages (for example, non-fermented teas such as green tea, semi-fermented teas such as oolong tea, whole fermented teas such as black tea, pu-erh teas etc. Post-fermented tea), fermented beverages (for example, alcoholic beverages such as lactic acid beverages, sake, wine, beer, medicinal liquor), smoothies, milk shakes and the like.
- tea beverages for example, non-fermented teas such as green tea, semi-fermented teas such as oolong tea, whole fermented teas such as black tea, pu-erh teas etc.
- Post-fermented tea fermented beverages
- fermented beverages for example, alcoholic beverages such as lactic acid beverages, sake, wine, beer, medicinal liquor
- smoothies milk shakes and the like.
- Food includes any processed food.
- processed food examples include, but are not limited to, bread, noodles, pasta, rice, confectionery (cake, ice cream, popsicle, donut, baked confectionery, candy, rice cake, ice confectionery, chewing gum, gummi, tablet confectionery, snack , Rice cakes, corn cups, and Japanese sweets such as dumplings and manju), tofu and processed products thereof, agricultural foods such as canned fruits, cooking liquor, medicinal liquor, mirin, vinegar, soy sauce, miso, salted, Vermont vinegar, sweet vinegar Fermented foods such as pickles, sweet vinegar ginger, vinegared lotus root, pickles, etc., livestock foods such as yogurt, ham, bacon, sausage, fishery products such as kamaboko, fried tempura, hampen, shimeji mushroom, soup, potage, jelly, boiled, dressing, Noodle soup, tempura sauce, hippo sauce, chilled Chinese sauce, grilled meat sauce, sauce, toothpaste, sweet potato , However winding, yakisoba source, paste products, seasoned seaweed, tenka
- processed foods are made from natural products, but the properties (eg, physical properties such as elasticity, viscosity, hardness, and sensory properties such as taste, smell, texture, etc.) are different from natural products. .
- the processed food contains non-natural ingredients.
- RebC-containing line (high RebC type line) in which the concentration of rebaudioside C (RebC) in the dried leaf is 5.68 to 9.96% by weight and the proportion of total steviol glycosides is 40% or more ) was obtained.
- these high RebC type lines had a common decrease in RebA production. (“STV” in the table represents stevioside). [Weight concentration in dry leaves] [Percentage of total steviol glycosides]
- the first generation (M1 generation) seeds were collected by self-breeding of all the M0 generation individuals. A total of 115 populations were prepared with a total of three EMS treatments. The M1 generation seeds were sown in a greenhouse in the Suntory Research Center to obtain M1 generation seedlings. An appropriate amount of fresh leaves was sampled from the M1 generation individuals, and steviol glycosides were quantified by LC / MS-MS (Shimadzu LCMS8050). Specifically, 0.25 g of fresh leaves were dried by freeze drying, and 0.05 g of dried crushed material was put into pure water.
- Genomic DNA was extracted from the Stevia leaf which wants to investigate the presence or absence of the gene polymorphism of this invention, and PCR was performed using the extracted genomic DNA as a template.
- Blend Taq Toyobo
- a reaction solution was prepared according to the instructions of Blend Taq.
- Amplification of the DNA fragment by PCR was performed using 5′-TGGTCACCCTCTAATCATGCTACCG-3 ′ (SEQ ID NO: 3) as an Fw primer and 5′-TTAACTCTCATGATCGATGGCAACCGCACGCGCATTCTTTTCCAAC-3 ′ (SEQ ID NO: 4) as Rv.
- PCR conditions were 95 ° C.
- the DNA fragment amplified by PCR was cleaved with a restriction enzyme (SpeI: Toyobo).
- SpeI Toyobo
- An enzyme reaction solution of 2 ⁇ L of H buffer, 1 ⁇ L of SpeI, and 5 ⁇ L of pure water was prepared in 12 ⁇ L of the reaction solution after PCR.
- the enzyme reaction solution was allowed to stand at 37 ° C. for 16 hours for enzyme reaction.
- the enzyme reaction solution after the restriction enzyme reaction was performed using LabChip GX Touch HT (Perkin elmer). A small amount of the enzyme reaction solution was electrophoresed on a DNA 5k / RNA CZE LabChip, the content of DNA in the mobile phase was detected by UV, a pseudo-electrophoresis image was prepared, and the marker was detected.
- the nucleotide sequence of each band of polynucleotide was analyzed.
- the base sequence (heterojunction) of the bands EM3-16-24, EM2-14-11, EM2-14-18, and EM2-14-30 is shown in SEQ ID NO: 5, and the base of the band EM-3-45-1
- the sequence (homozygous) is shown in SEQ ID NO: 6, and the base sequences of the bands of EM2-14-38, EM1-11, and EM2-2-4 are shown in SEQ ID NO: 7 (homozygous).
- the present invention makes it possible to provide rebaudioside C more efficiently, it is possible to provide a pharmaceutical, a fragrance, a food or drink, etc., in which the aftertreatment of sweetness by stevia is improved by containing a sufficient amount of rebaudioside C.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- General Health & Medical Sciences (AREA)
- Developmental Biology & Embryology (AREA)
- Environmental Sciences (AREA)
- Physiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Polymers & Plastics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Alternative & Traditional Medicine (AREA)
- Hematology (AREA)
- Birds (AREA)
- Diabetes (AREA)
- Child & Adolescent Psychology (AREA)
- Physics & Mathematics (AREA)
Abstract
Description
そこで、レバウジオシドCをさらにより多く含むステビア植物体の取得、そのような植物体を作出するための手段、そのような植物体より得られる乾燥葉、この乾燥葉より得られたレバウジオシドCを含む食物や飲料などの提供が望まれている。
本発明は、野生型ステビア種と比べレバウジオシドCを20%以上高い含量で含む高レバウジオシドC含有型非遺伝子組み換えステビア植物体であって、かつ総ステビオール配糖体に占めるレバウジオシドCの割合が40%以上である、前記植物体(以下、「本発明の植物体」)を提供する。
本発明のステビア植物体は、野生種のステビア植物体から派生した種であるが、レバウジオシドCが高くなるように遺伝子に変異が生じたものである。かつ当該遺伝子の変異は非遺伝子組換え的に生じるものである(後述)。
(1)野生型ステビア種と比べレバウジオシドAの含量(産生量)が低い。より具体的には、野生型ステビア種と比べレバウジオシドAの含量(例えば乾燥葉などにおける重量濃度)が、約40%以上、約50%以上、約60%以上、約70%以上、または、約80%以上低い。
(2)野生型ステビア種と比べステビオシドの含量(産生量)が低い。より具体的には、野生型ステビア種と比べステビオシドの含量(例えば乾燥葉などにおける重量濃度)が、約50%以上、約60%以上、約70%以上、または、約80%以上低い。
(3)野生型ステビア種と比べレバウジオシドFの含量(産生量)が高い。より具体的には、野生型ステビア種と比べレバウジオシドFの含量(例えば乾燥葉などにおける重量濃度)が、約2倍以上、約3倍以上、約4倍以上、約5倍以上、または、約6倍以上高い。
(5)野生型ステビア種と比べ、総ステビオール配糖体に占めるステビオシドの割合が低い。より具体的には、野生型ステビア種と比べ(例えば乾燥葉などにおける)総ステビオール配糖体に占めるステビオシドの割合が約30%以上、約40%以上、約50%以上、約60%以上、または、約70%以上低い。
(6)野生型ステビア種と比べ、総ステビオール配糖体に占めるレバウジオシドFの割合が高い。より具体的には、野生型ステビア種と比べ(例えば乾燥葉などにおける)総ステビオール配糖体に占めるレバウジオシドFの割合が約3倍以上、約4倍以上、約5倍以上、または、約6倍以上低い。
一部の態様において、本発明の植物体は、レバウジオシドCに係る上記特性に加え、野生型ステビア種と比べレバウジオシドAおよびステビオシドの含量(産生量)が低く、かつ、レバウジオシドFの含量(産生量)が高く、および/または、野生型ステビア種と比べ、総ステビオール配糖体に占めるレバウジオシドAおよびステビオシドの割合が低く、かつ、総ステビオール配糖体に占めるレバウジオシドFの割合が高い。
したがって、本発明のステビア植物体は、配列番号1に示す多型をゲノム中に有することを特徴とする。これらの多型は、高レバウジオシドC含有という表現型と統計学上の相関関係を有することが実施例において確認されている。
本発明のステビア植物体は前記遺伝子多型をヘテロ接合型で有していてもよく、あるいはホモ接合型で有していてもよい。一般に前記遺伝子多型をホモ接合型で有する植物体はヘテロ接合型と比べてレバウジオシドC含有量が高くなる傾向がある。
これらの遺伝子多型は、PCR法、TaqMan PCR法、シーケンス法、マイクロアレイ法、インベーダー法、TILLING法等により検出することが可能であるが、検出方法はこれらに限定されるものではない。遺伝子多型の検出方法の詳細については後述する。
あるいは、非遺伝子組換え的手法の例としてX線、γ線、紫外線などの放射線や光線を植物細胞に照射する方法もできる。この場合、適当な紫外線の照射量(紫外線ランプ強さ、距離、時間)を用いて照射した細胞を、選択培地などで培養させた後、目的の形質を有する細胞、カルス、植物体を選択できる。その際の照射強度は0.01~100Gr、0.03~75Gr、0.05~50Gr、0.07~25Gr、0.09~20Gr、0.1~15Gr、0.1~10Gr、0.5~10Gr、1~10Grであり、照射距離は1cm~200m、5cm~100m、7cm~75m、9cm~50m、10cm~30m、10cm~20m、10cm~10mであり、照射時間は1分~2年、2分~1年、3分~0.5年、4分~1か月、5分~2週間、10分~1週間である。照射の強度、距離及び時間は、放射線の線種や照射対象となる状態(細胞、カルス、植物体)により異なるが、当業者であれば適宜調整することができる。
また、細胞融合、葯培養(半数体育成)、遠縁交雑(半数体育成)などの手法も公知である。
一般に、植物細胞は、培養の間に変異を伴うことがあるため、より安定した形質維持のために植物個体に戻すことが好ましい。
なお、本発明の植物体は非遺伝子組み換えステビア植物体であるが、本発明の植物体を宿主として事後的に遺伝子組み換えを行って得られた植物体(例えば、本発明の植物体を宿主として遺伝子組み換えを行って、さらに別の形質を付加した植物体)も、本発明の範囲から除外されるものではない。
さらに、このようにして得られた抽出液に対し、酢酸エチルその他の有機溶媒:水の勾配、高速液体クロマトグラフィー(High Performance Liquid Chromatography:HPLC)、ガスクロマトグラフィー、飛行時間型質量分析(Time-of-Flight mass spectrometry:TOF-MS)、超高性能液体クロマトグラフィー (Ultra (High)Performance Liquid chromatography:UPLC) 等の公知の方法を用いることによりレバウジオシドCを精製することができる。
本発明は、別の実施態様において、本発明のステビア植物体と第2のステビア植物体とを交雑させる工程を含む、野生型ステビア種と比べレバウジオシドCを20%以上高い含量で含む高レバウジオシドC含有型ステビア植物体を作出する方法(以下、「本発明の作出方法」という)を提供する。
当該方法により作出される「野生型ステビア種と比べレバウジオシドCを20%以上高い含量で含む高レバウジオシドC含有型ステビア植物体」は、本発明の植物体と同じ表現型と遺伝的性質を有する。
本発明の植物体および本発明の植物体と同じ表現型と遺伝的性質を有する植物体は、当該植物体の組織から本発明の遺伝子多型を検出することによりスクリーニングすることができる。ここで、「スクリーニング」とは、本発明の植物体とそれ以外の植物体とを識別し、本発明の植物体を選択することを意味する。
したがって、本発明は、別の実施形態として、被験植物のゲノムに配列番号1に示す多型を同定する工程を含む、高レバウジオシドC含有型ステビア植物体をスクリーニングする方法(以下、「本発明のスクリーニング方法」という)を提供する。
(a) 本発明の遺伝子多型の塩基配列を含むオリゴヌクレオチドプローブ、及び/又は前記遺伝子の塩基配列及びその相補配列の少なくとも一方を増幅したときの増幅断片中に前記変異部位が含まれるように作製されたオリゴヌクレオチドプライマーを用いて被検ステビア植物体のゲノム又はcDNAライブラリーについて増幅処理及び/又はハイブリダイゼーション処理を行う工程、及び、
(b) 前記処理物を分析することにより変異部位を検出する工程
を含む、方法が挙げられる。
PCR法の場合、3’末端部分が本発明のSNPに相補的な配列を有するようなプライマーを作製することが好ましい。このように設計されたプライマーを用いると、鋳型となるサンプルが変異を有する場合には、プライマーが完全に鋳型にハイブリダイズするため、ポリメラーゼ伸長反応が進むが、鋳型が本発明のSNPを有しない場合には、プライマーの3’末端のヌクレオチドが鋳型とミスマッチを生じるので、伸長反応は起こらない。したがって、このようなプライマーを用いてPCR増幅を行い、増幅産物をアガロースゲル電気泳動などによって分析し、所定のサイズの増幅産物が確認できれば、サンプルである鋳型が変異を有していることになり、増幅産物が存在しない場合には、鋳型が変異を有していないものと判断できる。
あるいは、本発明のSNPとプライマー配列とは重複させず、かつ本発明の遺伝子多型をPCR増幅させることが可能なようにプライマー配列を設計し、増幅されたヌクレオチド断片の塩基配列をシーケンスすることにより、本発明の遺伝子多型を検出することができる。
PCR及びアガロースゲル電気泳動については、以下を参照:Sambrook, Fritsch and Maniatis, ”Molecular Cloning: A Laboratory Manual” 2nd Edition (1989), Cold Spring Harbor Laboratory Press。
シークエンス法とは、変異を含む領域をPCRにて増幅させ、Dye Terminatorなどを用いてDNA配列をシークエンスすることで、変異の有無を解析する方法である(Sambrook, Fritsch and Maniatis, ”Molecular Cloning: A Laboratory Manual” 2nd Edition (1989), Cold Spring Harbor Laboratory Press)。
DNAマイクロアレイは、ヌクレオチドプローブの一端が支持体上にアレイ状に固定されたものであり、DNAチップ、Geneチップ、マイクロチップ、ビーズアレイ等を含むものである。本発明の遺伝子多型と相補的な配列を含むプローブを用いることで、網羅的に本発明の遺伝子多型の有無を検出することができる。DNAチップなどのDNAマイクロアレイアッセイとしてはGeneChipアッセイが挙げられる(Affymetrix社;米国特許第6,045,996号、同第5,925,525号、及び同第5,858,659号参照)。GeneChip技術は、チップに貼り付けたオリゴヌクレオチドプローブの小型化高密度マイクロアレイを利用するものである。
インベーダー法とは、SNP等の遺伝子多型のそれぞれのアレルに特異的な2種類のレポータープローブ及び1種類のインベーダープローブの鋳型DNAへのハイブリダイゼーションと、DNAの構造を認識して切断するという特殊なエンドヌクレアーゼ活性を有するCleavase酵素によるDNAの切断を組み合わせた方法である(Livak, K. J. Biomol. Eng. 14, 143-149 (1999); Morris T. et al., J. Clin.Microbiol. 34, 2933 (1996); Lyamichev, V. et al., Science, 260, 778-783 (1993)等)。
TILLING(Targeting Induced Local Lesions IN Genomes)法とは、変異導入した突然変異体集団のゲノム中の変異ミスマッチをPCR増幅とCEL Iヌクレアーゼ処理によってスクリーニングする方法である。
本発明のさらなる態様において、本発明の植物体、または当該植物体の種子若しくは乾燥葉から抽出物を得る工程を含む、レバウジオシドC含有抽出物の製造方法(以下、「本発明の抽出物の製造方法」という)が提供される。さらに、本発明の抽出物の製造方法により得られた抽出物からレバウジオシドCを精製する工程を含む、レバウジオシドCの製造方法(以下、「本発明のレバウジオシドCの製造方法」という)が提供される。
レバウジオシドC含有抽出物は、本発明の植物体の新鮮葉または乾燥葉に適切な溶媒(水等の水性溶媒又はアルコール、エーテル及びアセトン等の有機溶媒)を反応させることにより得ることができる。抽出条件等はWO2016/090460に記載の方法や、後述の実施例に記載の方法を参照することができる。
また、レバウジオシドC含有抽出物を酢酸エチルその他の有機溶媒:水の勾配、高速液体クロマトグラフィー(High Performance Liquid Chromatography:HPLC)、ガスクロマトグラフィー、飛行時間型質量分析(Time-of-Flight mass spectrometry:TOF-MS)、超高性能液体クロマトグラフィー (Ultra (High)Performance Liquid chromatography:UPLC) 等の公知の方法を用いることによりレバウジオシドCを精製することができる。
食品は任意の加工食品を包含する。加工食品の例としては、限定されずに、パン、麺類、パスタ、ごはん、菓子類(ケーキ、アイスクリーム、アイスキャンデー、ドーナツ、焼き菓子、キャンデー、飴、氷菓、チューインガム、グミ、錠菓、スナック、米菓、コーンカップ、並びに団子及びまんじゅう等の和菓子)、豆腐及びその加工品、フルーツ缶詰等の農産食品、料理酒、薬用酒、みりん、食酢、醤油、みそ、塩辛、バーモント酢、甘酢らっきょ漬け、甘酢生姜、酢レンコン、漬物等の発酵食品、ヨーグルト、ハム、ベーコン、ソーセージ等の畜産食品、かまぼこ、揚げ天、はんぺん、しめ鯖等の水産食品、スープ、ポタージュ、ゼリー、佃煮、ドレッシング、麺つゆ、天ぷらのタレ、カバ焼きのタレ、冷やし中華のタレ、焼肉のタレ、ソース、歯磨きペースト、さつま揚げ、だし巻き、焼きそばソース、練り製品、味付け海苔、天カス、ふりかけなどが挙げられる。一態様において、加工食品は天然物を原料とするが、天然物とはその特性(例えば、弾力性、粘性、硬度などの物理的特性、味、匂い、食感などの官能的特性)が異なる。別の態様において、加工食品は非天然成分を含む。
野生型ステビア種子(タイ国での市販品種、2014年8月に導入)約2000個(重量換算)を3つに分けて、各々に対して0.1%、0.2%又は0.3%のエチレンメタンスルホン酸(EMS)処理を行って遺伝子改変を行った。
このEMS処理済み種子及び無処理の種子を、サントリー研究センター内温室にて播種し、EMS処理当代(M0世代)苗および無処理苗を得た。処理濃度間での発芽率差異は見られなかった。
EMS処理当代(M0世代)および無処理個体より適量の新鮮葉をサンプリングし、LC/MS-MS(島津LCMS8050)にて各ステビオール配糖体の濃度を定量した。具体的には、0.25gの新鮮葉をフリーズドライにより乾燥し、破砕物乾物0.05gを純水中に投入した。超音波処理20分にて抽出し、遠心・濾過した後に0.33mlの抽出液を得た。この抽出液をLCMS8050イオンモード(島津LCMS8050)にてLC/MS-MS分析を行ったところ、以下の分析結果が得られた。分析結果を以下の表に示す(表1-1、表1-2)。表中、EMの後の数字が処理濃度を示す(すなわち、EM1=0.1%処理)。
各植物体のスクリーニングの結果、乾燥葉中のレバウジオシドC(RebC)の濃度が5.68~9.96重量%であり、かつ総ステビオール配糖体に占める割合が40%以上のRebC含有系統(高RebC型系統)を複数得た。なお、これら高RebC型系統は共通してRebA生産量が低下していた。(表中「STV」はステビオシドを表す)。
[乾燥葉中の重量濃度]
[総ステビオール配糖体中の割合]
上記M0世代全個体の自殖により処理第一代(M1世代)種子を採種した。3種EMS処理合計で115集団を作製した。
上記M1世代種子をサントリー研究センター内の温室内で播種し、M1世代苗を得た。上記M1世代個体より適量の新鮮葉をサンプリングし、LC/MS-MS(島津LCMS8050)にてステビオール配糖体を定量した。
具体的には、0.25gの新鮮葉をフリーズドライにより乾燥し、破砕物乾物0.05gを純水中に投入した。超音波処理20分にて抽出し、遠心・濾過した後に0.33mlの抽出液を得た。この抽出液をLCMS8050イオンモード(島津LCMS8050)にてLC/MS-MS分析を行ったところ、以下の分析結果が得られた(表2-1、表2-2)。
表中、EMの後の数字は処理濃度を表す(すなわち、EM1=0.1%処理)。
分析結果に基づき、高RebC個体を複数選抜した。
○高RebC型系統
[乾燥葉中の重量濃度]
[総ステビオール配糖体中の割合]
○低RebC型もしくは通常濃度の系統
[乾燥葉中の重量濃度]
[ステビオール配糖体中の割合]
高RebC型系統についてさらにRebOおよびRebN濃度を定量した。定量条件は上記と同じである。RebC、RebO、RebNは共通して、分子内にラムノース残基を有するため、糖の転移に関与する同一の酵素がこれらの含有比率に影響しているのではないかと仮定し、各成分の濃度が比例関係にある場合に本仮説を支持できると考え実施したものである。
[乾燥葉中の重量濃度]
[総ステビオール配糖体中の割合]
本発明の遺伝子多型の有無を調査したいステビア葉からゲノムDNAを抽出し、抽出したゲノムDNAを鋳型にPCRを行った。PCRはBlend Taq(東洋紡)を使用しBlend Taqの説明書に従い反応液を作製した。PCRによるDNA断片の増幅にはFwプライマーとして 5’-TGGTCACCCTCTAATCATGCTACCG-3’ (配列番号3)とRvとして 5’-TTAACTCTCATGATCGATGGCAACCGCACGCGCATTCTTTTCCAAC-3’ (配列番号4)を用いてPCRを行った。PCRの条件は95℃ 2分、55℃ 30秒、72℃ 30秒の3段階の反応を35回繰り返した。PCRで増幅したDNA断片は制限酵素(SpeI:東洋紡)で切断した。PCR後の反応液12μLにH buffer 2μL、SpeI 1μL、純水5μLの酵素反応液を作製した。酵素反応液は37℃で16時間静置し酵素反応させた。制限酵素反応後の酵素反応液はLabChip GX Touch HT(Perkin elmer社)を使って行った。微量の酵素反応液をDNA 5k/RNA CZE LabChip上で電気泳動を行い、UVにより移動相内のDNAの含量を検出し疑似的な電気泳動像を作製しマーカーの検出を行った。
各バンドのポリヌクレオチドについて塩基配列を解析した。EM3-16-24、EM2-14-11、EM2-14-18、EM2-14-30のバンドの塩基配列(ヘテロ接合)を配列番号5に示し、EM-3-45-1のバンドの塩基配列(ホモ接合)を配列番号6に示し、及びEM2-14-38、EM1-11、EM2-2-4のバンドの塩基配列を配列番号7(ホモ接合)に示す。
つまり、検定交雑の結果、高RebC型:低RebC型は1:1に分離したため、マーカー検定結果と表現型は一定の関係にあり、本SNPによってRebC遺伝子型を規定できることが判明した。
以上の結果から、本発明の遺伝子多型の有無について本手順を用いると、RebC濃度が高い個体を遺伝子レベルで検出することが可能であることが判明した。
Claims (16)
- 野生型ステビア種と比べレバウジオシドCを20%以上高い含量で含む高レバウジオシドC含有型非遺伝子組み換えステビア植物体であって、かつ総ステビオール配糖体に占めるレバウジオシドCの割合が40%以上である、前記植物体。
- 乾燥葉として7重量%以上のレバウジオシドC含量を有する、請求項1に記載の植物体。
- 配列番号1に示す多型をゲノム中に有する、請求項1又は2に記載の植物体。
- 請求項1~3のいずれか一項に記載の植物体の種子。
- 請求項1~3のいずれか一項に記載の植物体の乾燥葉。
- 請求項1~3のいずれか一項に記載の植物体の組織培養物又は植物培養細胞。
- 胚、分裂組織細胞、花粉、葉、根、根端、花弁、プロトプラスト、葉の切片およびカルスである請求項6記載の組織培養物又は植物培養細胞。
- 請求項1~3のいずれか一項に記載のステビア植物体と第2のステビア植物体とを交雑させる工程を含む、野生型ステビア種と比べレバウジオシドCを20%以上高い含量で含む高レバウジオシドC含有型ステビア植物体を作出する方法。
- 第2の植物体が請求項1~3のいずれか一項に記載のステビア植物体である、請求項8に記載の方法。
- 請求項1~3のいずれか一項に記載の植物体、請求項4に記載の種子又は請求項5に記載の乾燥葉の抽出物。
- 請求項10に記載の抽出物を含む医薬品、香料又は飲食品。
- 請求項1~3のいずれか一項に記載の植物体、請求項4に記載の種子又は請求項5に記載の乾燥葉から抽出物を得る工程を含む、レバウジオシドC含有抽出物の製造方法。
- 請求項12に記載のレバウジオシドC含有抽出物からレバウジオシドCを精製する工程を含む、レバウジオシドCの製造方法。
- 請求項12に記載の方法により得られる抽出物及び/又は請求項13に記載の方法により得られるレバウジオシドCと他の成分とを混合する工程を含む、医薬品、香料又は飲食品の製造方法。
- 被験植物のゲノムに配列番号1に示す多型を同定する工程を含む、高レバウジオシドC含有型ステビア植物体をスクリーニングする方法。
- さらに、葉組織のレバウジオシドCの含有量を測定する工程を含む、請求項15に記載の方法。
Priority Applications (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BR112019013210A BR112019013210A2 (pt) | 2016-12-27 | 2017-12-26 | planta estévia não geneticamente modificada, semente, folha seca, cultura de tecido ou uma célula de planta cultivada, métodos para produzir uma planta estévia, um extrato, rebaudiosídeo c, um medicamento, um flavorizante ou um alimento ou bebida e para classificar uma planta estévia, extrato, e, medicamento, flavorizante ou alimento ou bebida. |
JP2018559553A JP7128117B2 (ja) | 2016-12-27 | 2017-12-26 | 高レバウジオシドc含有ステビア植物 |
AU2017388705A AU2017388705B2 (en) | 2016-12-27 | 2017-12-26 | High rebaudioside C-content stevia plant |
NZ754482A NZ754482B2 (en) | 2017-12-26 | High rebaudioside c-content stevia plant | |
EP23181900.4A EP4273230A3 (en) | 2016-12-27 | 2017-12-26 | High rebaudioside c-content stevia plant |
CN201780079622.XA CN110114459B (zh) | 2016-12-27 | 2017-12-26 | 瑞鲍迪苷c高含量的甜菊植物 |
EP17886105.0A EP3569707B1 (en) | 2016-12-27 | 2017-12-26 | High rebaudioside c-content stevia plant |
US16/473,094 US11284576B2 (en) | 2016-12-27 | 2017-12-26 | High rebaudioside C-content stevia plant |
ES17886105T ES2959827T3 (es) | 2016-12-27 | 2017-12-26 | Planta de estevia con alto contenido de rebaudiósido C |
US17/704,490 US20220217933A1 (en) | 2016-12-27 | 2022-03-25 | High rebaudioside c-content stevia plant |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2016-253543 | 2016-12-27 | ||
JP2016253543 | 2016-12-27 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/473,094 A-371-Of-International US11284576B2 (en) | 2016-12-27 | 2017-12-26 | High rebaudioside C-content stevia plant |
US17/704,490 Division US20220217933A1 (en) | 2016-12-27 | 2022-03-25 | High rebaudioside c-content stevia plant |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2018124142A1 true WO2018124142A1 (ja) | 2018-07-05 |
Family
ID=62707707
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2017/046805 WO2018124142A1 (ja) | 2016-12-27 | 2017-12-26 | 高レバウジオシドc含有ステビア植物 |
Country Status (8)
Country | Link |
---|---|
US (2) | US11284576B2 (ja) |
EP (2) | EP4273230A3 (ja) |
JP (1) | JP7128117B2 (ja) |
CN (1) | CN110114459B (ja) |
AU (1) | AU2017388705B2 (ja) |
BR (1) | BR112019013210A2 (ja) |
ES (1) | ES2959827T3 (ja) |
WO (1) | WO2018124142A1 (ja) |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020027155A1 (ja) | 2018-07-31 | 2020-02-06 | サントリーホールディングス株式会社 | 甘味成分高含有型ステビア植物及びそのスクリーニング方法 |
WO2020138366A1 (ja) * | 2018-12-28 | 2020-07-02 | サントリーホールディングス株式会社 | 高ブロウソネチン含有ステビア植物 |
WO2020209265A1 (ja) | 2019-04-11 | 2020-10-15 | サントリーホールディングス株式会社 | 花芽形成能の低いステビア植物 |
WO2020209266A1 (ja) | 2019-04-11 | 2020-10-15 | サントリーホールディングス株式会社 | 花粉形成能の低いステビア植物 |
WO2021020517A1 (ja) * | 2019-07-31 | 2021-02-04 | サントリーホールディングス株式会社 | 新規ステビオール配糖体を含む植物体 |
WO2021061805A1 (en) * | 2019-09-24 | 2021-04-01 | Purecircle Usa Inc. | Stevia cultivar '320032' with super high rebaudioside a content |
JPWO2021020516A1 (ja) * | 2019-07-31 | 2021-10-28 | サントリーホールディングス株式会社 | 新規ステビオール配糖体およびその製造方法、ならびにそれを含む甘味料組成物 |
WO2021230258A1 (ja) * | 2020-05-12 | 2021-11-18 | サントリーホールディングス株式会社 | 高レバウジオシドe含有ステビア植物体 |
WO2021230259A1 (ja) * | 2020-05-12 | 2021-11-18 | サントリーホールディングス株式会社 | 高ステビオール配糖体含有ステビア植物及びそのスクリーニング方法 |
WO2022220152A1 (ja) | 2021-04-15 | 2022-10-20 | サントリーホールディングス株式会社 | 栄養成分リッチなステビア植物 |
WO2024005142A1 (ja) * | 2022-06-30 | 2024-01-04 | サントリーホールディングス株式会社 | ステビア植物のスクリーニング方法 |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5858659A (en) | 1995-11-29 | 1999-01-12 | Affymetrix, Inc. | Polymorphism detection |
US5925525A (en) | 1989-06-07 | 1999-07-20 | Affymetrix, Inc. | Method of identifying nucleotide differences |
US6045996A (en) | 1993-10-26 | 2000-04-04 | Affymetrix, Inc. | Hybridization assays on oligonucleotide arrays |
JP2009517043A (ja) | 2005-11-23 | 2009-04-30 | ザ・コカ−コーラ・カンパニー | ビタミンを含む高甘味度甘味料組成物及びこれにより甘味を付与された組成物 |
JP2012504552A (ja) | 2008-10-03 | 2012-02-23 | 守田化学工業株式会社 | 新規ステビオール配糖体 |
US8501261B2 (en) * | 2010-05-21 | 2013-08-06 | Purecircle Sdn Bhd | High-purity Rebaudioside C and process for purification of the same |
US20130284164A1 (en) * | 2011-01-14 | 2013-10-31 | Glg Life Tech Corporation | Processes of Purifying Steviol Glycosides Reb C |
JP2016515814A (ja) | 2013-03-15 | 2016-06-02 | カーギル・インコーポレイテッド | 増大したレバウジオシドd含量を有するステビア属植物 |
WO2016090460A1 (en) | 2014-12-08 | 2016-06-16 | Qibin Wang | High rebaudioside-c plant varietal and compositions extracted therefrom with high rebaudioside-c and total steviol glycoside content |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
USPP10563P (en) * | 1996-05-29 | 1998-08-18 | Royal-Sweet International Technologies Ltd. Part. | Stevia plant named `RSIT 95-166-13` |
US9894922B2 (en) | 2011-05-18 | 2018-02-20 | Purecircle Sdn Bhd | Glucosyl rebaudioside C |
CN103875343B (zh) | 2012-12-21 | 2018-03-30 | 丰益(上海)生物技术研发中心有限公司 | 提高甜叶菊中莱鲍迪苷a、甜菊糖苷、莱鲍迪苷c和/或总糖苷含量的方法 |
WO2016049531A1 (en) * | 2014-09-26 | 2016-03-31 | Purecircle Usa Inc. | Single nucleotide polymorphism (snp) markers for stevia |
SG11201908370VA (en) | 2017-03-31 | 2019-10-30 | Suntory Holdings Ltd | Novel steviol glycoside and production method therefor, and sweetener composition containing same |
-
2017
- 2017-12-26 EP EP23181900.4A patent/EP4273230A3/en active Pending
- 2017-12-26 AU AU2017388705A patent/AU2017388705B2/en active Active
- 2017-12-26 BR BR112019013210A patent/BR112019013210A2/pt unknown
- 2017-12-26 EP EP17886105.0A patent/EP3569707B1/en active Active
- 2017-12-26 CN CN201780079622.XA patent/CN110114459B/zh active Active
- 2017-12-26 WO PCT/JP2017/046805 patent/WO2018124142A1/ja unknown
- 2017-12-26 US US16/473,094 patent/US11284576B2/en active Active
- 2017-12-26 ES ES17886105T patent/ES2959827T3/es active Active
- 2017-12-26 JP JP2018559553A patent/JP7128117B2/ja active Active
-
2022
- 2022-03-25 US US17/704,490 patent/US20220217933A1/en active Pending
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5925525A (en) | 1989-06-07 | 1999-07-20 | Affymetrix, Inc. | Method of identifying nucleotide differences |
US6045996A (en) | 1993-10-26 | 2000-04-04 | Affymetrix, Inc. | Hybridization assays on oligonucleotide arrays |
US5858659A (en) | 1995-11-29 | 1999-01-12 | Affymetrix, Inc. | Polymorphism detection |
JP2009517043A (ja) | 2005-11-23 | 2009-04-30 | ザ・コカ−コーラ・カンパニー | ビタミンを含む高甘味度甘味料組成物及びこれにより甘味を付与された組成物 |
JP2012504552A (ja) | 2008-10-03 | 2012-02-23 | 守田化学工業株式会社 | 新規ステビオール配糖体 |
US8501261B2 (en) * | 2010-05-21 | 2013-08-06 | Purecircle Sdn Bhd | High-purity Rebaudioside C and process for purification of the same |
US20130284164A1 (en) * | 2011-01-14 | 2013-10-31 | Glg Life Tech Corporation | Processes of Purifying Steviol Glycosides Reb C |
JP2016515814A (ja) | 2013-03-15 | 2016-06-02 | カーギル・インコーポレイテッド | 増大したレバウジオシドd含量を有するステビア属植物 |
WO2016090460A1 (en) | 2014-12-08 | 2016-06-16 | Qibin Wang | High rebaudioside-c plant varietal and compositions extracted therefrom with high rebaudioside-c and total steviol glycoside content |
Non-Patent Citations (6)
Title |
---|
"Protocols for in vitro cultures and secondary metabolite analysis of aromatic and medicinal plants", METHOD IN MOLECULAR BIOLOGY, vol. 1391, pages 113 - 123 |
LIVAK, K. J. GENET, ANAL., vol. 14, 1999, pages 143 |
LIVAK, K., J. BIOMOL. ENG., vol. 14, 1999, pages 143 - 149 |
LYAMICHEV, V. ET AL., SCIENCE, vol. 260, 1993, pages 778 - 783 |
MORRIS T. ET AL., J. CLIN. MICROBIOL., vol. 34, 1996, pages 2933 |
SAMBROOK: "Molecular Cloning: A Laboratory Manual", 1989, COLD SPRING HARBOR LABORATORY PRESS, article "Fritsch and Maniatis" |
Cited By (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020027155A1 (ja) | 2018-07-31 | 2020-02-06 | サントリーホールディングス株式会社 | 甘味成分高含有型ステビア植物及びそのスクリーニング方法 |
JP7337068B2 (ja) | 2018-07-31 | 2023-09-01 | サントリーホールディングス株式会社 | 甘味成分高含有型ステビア植物及びそのスクリーニング方法 |
CN112469837A (zh) * | 2018-07-31 | 2021-03-09 | 三得利控股株式会社 | 甜味成分高含有型甜菊植物及其筛选方法 |
US11732313B2 (en) | 2018-07-31 | 2023-08-22 | Suntory Holdings Limited | High-sweetening-content stevia plant and method for screening same |
JPWO2020027155A1 (ja) * | 2018-07-31 | 2021-08-02 | サントリーホールディングス株式会社 | 甘味成分高含有型ステビア植物及びそのスクリーニング方法 |
WO2020138366A1 (ja) * | 2018-12-28 | 2020-07-02 | サントリーホールディングス株式会社 | 高ブロウソネチン含有ステビア植物 |
CN113226344A (zh) * | 2018-12-28 | 2021-08-06 | 三得利控股株式会社 | 富含构树碱的甜菊植物 |
WO2020209265A1 (ja) | 2019-04-11 | 2020-10-15 | サントリーホールディングス株式会社 | 花芽形成能の低いステビア植物 |
WO2020209266A1 (ja) | 2019-04-11 | 2020-10-15 | サントリーホールディングス株式会社 | 花粉形成能の低いステビア植物 |
WO2021020517A1 (ja) * | 2019-07-31 | 2021-02-04 | サントリーホールディングス株式会社 | 新規ステビオール配糖体を含む植物体 |
JPWO2021020516A1 (ja) * | 2019-07-31 | 2021-10-28 | サントリーホールディングス株式会社 | 新規ステビオール配糖体およびその製造方法、ならびにそれを含む甘味料組成物 |
JP7002703B2 (ja) | 2019-07-31 | 2022-02-04 | サントリーホールディングス株式会社 | 新規ステビオール配糖体およびその製造方法、ならびにそれを含む甘味料組成物 |
CN114173555A (zh) * | 2019-07-31 | 2022-03-11 | 三得利控股株式会社 | 含有新型甜菊醇糖苷的植物体 |
AU2020320849B2 (en) * | 2019-07-31 | 2023-11-16 | Suntory Holdings Limited | Novel steviol glycoside, method for producing same, and sweetener composition containing same |
CN114929013B (zh) * | 2019-09-24 | 2024-05-14 | 谱赛科美国股份有限公司 | 具有超高莱鲍迪苷a含量的甜菊栽培品种‘320032’ |
CN114929013A (zh) * | 2019-09-24 | 2022-08-19 | 谱赛科美国股份有限公司 | 具有超高莱鲍迪苷a含量的甜菊栽培品种‘320032’ |
WO2021061805A1 (en) * | 2019-09-24 | 2021-04-01 | Purecircle Usa Inc. | Stevia cultivar '320032' with super high rebaudioside a content |
WO2021230258A1 (ja) * | 2020-05-12 | 2021-11-18 | サントリーホールディングス株式会社 | 高レバウジオシドe含有ステビア植物体 |
WO2021230259A1 (ja) * | 2020-05-12 | 2021-11-18 | サントリーホールディングス株式会社 | 高ステビオール配糖体含有ステビア植物及びそのスクリーニング方法 |
WO2022220152A1 (ja) | 2021-04-15 | 2022-10-20 | サントリーホールディングス株式会社 | 栄養成分リッチなステビア植物 |
WO2024005142A1 (ja) * | 2022-06-30 | 2024-01-04 | サントリーホールディングス株式会社 | ステビア植物のスクリーニング方法 |
Also Published As
Publication number | Publication date |
---|---|
EP3569707A4 (en) | 2020-09-30 |
US20200170209A1 (en) | 2020-06-04 |
JPWO2018124142A1 (ja) | 2019-10-31 |
EP3569707A1 (en) | 2019-11-20 |
EP3569707B1 (en) | 2023-07-26 |
JP7128117B2 (ja) | 2022-08-30 |
US11284576B2 (en) | 2022-03-29 |
NZ754482A (en) | 2023-09-29 |
EP4273230A2 (en) | 2023-11-08 |
BR112019013210A2 (pt) | 2019-12-10 |
ES2959827T3 (es) | 2024-02-28 |
EP4273230A3 (en) | 2023-12-06 |
AU2017388705B2 (en) | 2024-03-14 |
US20220217933A1 (en) | 2022-07-14 |
CN110114459A (zh) | 2019-08-09 |
CN110114459B (zh) | 2024-03-19 |
AU2017388705A1 (en) | 2019-07-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7128117B2 (ja) | 高レバウジオシドc含有ステビア植物 | |
JP2023075257A (ja) | 高レバウジオシドm含有ステビア植物 | |
US20130347140A1 (en) | High Rebaudioside-A Plant and Methods of Producing the Same and Uses Thereof | |
CN113016623A (zh) | 用于甜菊的单核苷酸多态性(snp)标志物 | |
US20170290285A1 (en) | High rebaudioside-c plant varietal and compositions extracted therefrom with high rebaudioside-c and total steviol glycoside content | |
JP7337068B2 (ja) | 甘味成分高含有型ステビア植物及びそのスクリーニング方法 | |
US20240138331A1 (en) | High Rebaudioside M Stevia Plant Cultivars and Methods of Producing the Same | |
WO2021230257A1 (ja) | レバウジオシドm含有比の高いステビア植物及びそのスクリーニング方法 | |
US20180042280A1 (en) | High rebaudioside-a plant varietal, methods of extraction and purification therefrom, of compositions with enhanced rebaudioside-a content and uses of said composition | |
Madarbokus et al. | Identification of genetic diversity among papaya varieties in Mauritius using morphological and molecular markers | |
R Abdelsalam et al. | Genetic improvement through selection of different Stevia rebaudiana genotypes | |
JPWO2020138364A1 (ja) | 高レバウジオシドd含有ステビア植物 | |
JP2023053015A (ja) | 青汁用の飲食用組成物 | |
WO2021230256A1 (ja) | 高レバウジオシドd含有ステビア植物 | |
WO2021230259A1 (ja) | 高ステビオール配糖体含有ステビア植物及びそのスクリーニング方法 | |
CN113365492A (zh) | 非整倍体甜菊栽培品种“ap-1” | |
WO2021230258A1 (ja) | 高レバウジオシドe含有ステビア植物体 | |
US20160338396A1 (en) | High Rebaudioside-A Plant and Methods of Producing the Same and Uses Thereof | |
Singh et al. | Molecular and functional diversity in Capsicum landraces of Andaman Islands | |
CN104270939A (zh) | 具有部分加倍或完全加倍的基因组的栽培高粱植物及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 17886105 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2018559553 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112019013210 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 2017388705 Country of ref document: AU Date of ref document: 20171226 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2017886105 Country of ref document: EP Effective date: 20190729 |
|
ENP | Entry into the national phase |
Ref document number: 112019013210 Country of ref document: BR Kind code of ref document: A2 Effective date: 20190625 |